AR041672A1 - Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo - Google Patents

Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo

Info

Publication number
AR041672A1
AR041672A1 ARP030103815A ARP030103815A AR041672A1 AR 041672 A1 AR041672 A1 AR 041672A1 AR P030103815 A ARP030103815 A AR P030103815A AR P030103815 A ARP030103815 A AR P030103815A AR 041672 A1 AR041672 A1 AR 041672A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
heterocyclyl
independently represent
aryl
Prior art date
Application number
ARP030103815A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR041672A1 publication Critical patent/AR041672A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto bicíclico de benzamida, o una de sus sales farmacéuticamente aceptables, que tiene la fórmula (1) en la que R1 y R2 representan independientemente halógeno, hidroxi, ciano, nitro, oxo, haloalquilo C1-6, polihaloalquilo C1-6, haloalcoxi C1-6, polihaloalcoxi C1-6, alquilo C1-6, alcoxi C1-6, arilalcoxi C1-6, (alquil C1-6)tio, (alcoxi C1-6)alquilo C1-6; (cicloalquil C3-7)alcoxi C1-6, alcanoilo C1-6, (alcoxi C1-6)carbonilo, arilo, heteroarilo, heterociclilo, arilalquilo C1-6, heteroarilalquilo C1-6, heterociclilaquilo C1-6, (alquil C1-6)sulfonilo, (alquil C1-6)sulfinilo, (alquil C1-6)sulfoniloxi, (alquil C1-6)sulfonilalquilo C1-6, arilsulfonilo, arilsulfoniloxi, arilsulfonilalquilo C1-6, ariloxi, -CO-arilo, -CO-heterociclilo, -CO-heteroarilo, (alquil C1-6)sulfonamidoalquilo C1-6, (alquil C1-6)amidoalquilo C1-6, arilsulfonamido, arilamidosulfonilo, arilsulfonamidoalquilo C1-6, arilcarboxamidoalquilo C1-6, arilalquilo C1-6, arilalcanoilo C1-6, o un grupo NR15R16, -NR15CO-arilo, -NR15CO-heterociclilo, -NR15CO-heteroarilo, -CONR15R16, -NR15COR16, -NR15SO2R16 o -SO2NR15R16, donde R15 y R16 representan independientemente H o alquilo C1-6, donde dichos grupos arilo, heteroarilo y heterociclilo de R1 y R2 pueden estar opcionalmente sustituidos con uno o más (por ejemplo, 1, 2, o 3) sustituyentes que pueden ser iguales o diferentes y que se seleccionan entre halógeno, alquilo C1-6, alcoxi C1-6, oxo, -CF3, -OCF3, -CN, alcanoilo C1-6, (alquil C1-6)sulfonilo, (alquil C1-6)sulfoniloxi, (alquil C1-6)amido o (alquil C1-6)sulfonamido; a y b representan independientemente, 0, 1 o 2, de tal modo que a y b no pueden representar ambos 0; = es un enlace sencillo o doble; R3 representa halógeno, alquilo C1-6, alcoxi C1-6, ciano, amino o trifluorometilo; m y n representan independientemente, 0 1 o 2; p representa un número entero de 0 a 3, de tal modo que cuando p es un número entero mayor que 1, dos grupos R1 pueden en cambio estar unidos para formar un grupo heterociclilo; R4 representa -(CH2)q-NR11R12 o un grupo de la fórmula (2) en la que q es 2, 3, o 4; R11 y R112 representan independientemente alquilo C1-6 o junto con el átomo de N al que están unidos representan un grupo heterocíclico unido a N, opcionalmente sustituido con uno o dos grupos R17; R13 representa H, alquilo C1-6, cicloalquilo C3-8, -(alquil C1-6)-arilo o heterociclilo; R14 y R17 representan independientemente halógeno, alquilo C1-6, haloalquilo C1-6, -OH, di(alquil C1-6)amino o alcoxi C1-6; f y k representan independientemente 0, 1, o 2; g es 0, 1 o 2 y h es 0, 1, 2 o 3, de tal modo que g y h no pueden ser ambos 0; o sus solvatos. Los compuestos bicíclicos de benzamida de la fórmula (1) tienen actividad farmacológica, siendo útiles para preparar composiciones farmacéuticas para el tratamiento de trastornos neurológicos y psiquiátricos. Se propone un procedimiento para la preparación de un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables.
ARP030103815A 2002-10-22 2003-10-20 Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo AR041672A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0224557.9A GB0224557D0 (en) 2002-10-22 2002-10-22 Novel compounds
GBGB0306328.6A GB0306328D0 (en) 2002-10-22 2003-03-19 Novel compounds

Publications (1)

Publication Number Publication Date
AR041672A1 true AR041672A1 (es) 2005-05-26

Family

ID=32178875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103815A AR041672A1 (es) 2002-10-22 2003-10-20 Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo

Country Status (11)

Country Link
US (2) US7446103B2 (es)
EP (1) EP1554243B1 (es)
JP (1) JP2006505623A (es)
AR (1) AR041672A1 (es)
AT (1) ATE346044T1 (es)
AU (1) AU2003278119A1 (es)
DE (1) DE60309913T2 (es)
ES (1) ES2276125T3 (es)
GB (2) GB0224557D0 (es)
TW (1) TW200418839A (es)
WO (1) WO2004037788A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
WO2003022813A1 (fr) * 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives indole, methode de fabrication et medicaments renfermant lesdits derives en tant que principe actif
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
MXPA05006567A (es) 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
EP2189448B1 (en) 2003-06-17 2014-01-29 Arena Pharmaceuticals, Inc. Processes for the Separation of 3-Benzazepine Racemates
PL1755593T3 (pl) 2004-06-02 2008-06-30 Hoffmann La Roche Pochodne naftalenu przydatne jako ligandy 3-receptora histaminowego
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. C형 간염 치료 방법
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1632494A1 (en) * 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
KR101281919B1 (ko) 2004-12-21 2013-07-03 아레나 파마슈티칼스, 인크. (r)-8-클로로-1-메틸-2,3,4,5-테트라히드로-1h-3-벤즈아제핀 히드로클로라이드의 결정질 형태
PT1833473E (pt) 2004-12-23 2009-12-17 Arena Pharm Inc Composições de modulador de receptor 5ht2c e métodos de utilização
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717234A1 (en) * 2005-04-29 2006-11-02 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2007050124A1 (en) * 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Fused piperidine derivatives and their uses as therapeutic agents
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
EP2001852A2 (en) 2006-04-03 2008-12-17 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
MX2008013196A (es) * 2006-04-12 2008-10-22 Hoffmann La Roche 5-amido-2-carboxiamida-indoles.
US7928238B2 (en) 2006-05-11 2011-04-19 Janssen Pharmaceutica Nv 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors
JP2009536954A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Cetp阻害剤としての3,4−ジヒドロ−2h−ベンゾ[1,4]オキサジンおよびチアジン誘導体
CA2670285A1 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
US7648979B2 (en) * 2007-02-07 2010-01-19 Hoffmann-La Roche Inc. 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
NZ580802A (en) 2007-05-10 2012-09-28 Albany Molecular Res Inc Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
CN101903338A (zh) 2007-12-19 2010-12-01 安姆根有限公司 用作炎症调节剂的苯基乙酸衍生物
JP5491421B2 (ja) 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2cアゴニストである(r)−8−クロロ−1−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピンに関連する中間体の調製のためのプロセス
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2246331A1 (en) * 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
US8802696B2 (en) * 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
AU2010247735B2 (en) * 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
CN102648170A (zh) 2009-06-18 2012-08-22 艾尼纳制药公司 制备5-ht2c受体激动剂的方法
EP2459529A1 (en) * 2009-07-02 2012-06-06 Cephalon, Inc. Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
EP2371808A1 (en) * 2010-03-08 2011-10-05 Ratiopharm GmbH Process for preparing dronedarone
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
ES2704455T3 (es) 2010-09-01 2019-03-18 Arena Pharm Inc Formas farmacéuticas de liberación modificada de agonistas de 5-HT2C útiles para la gestión del peso
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
EP2939677A1 (en) 2010-09-01 2015-11-04 Arena Pharmaceuticals, Inc. Administration of lorcaserin to indviduals with renal impairment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
WO2015074064A2 (en) 2013-11-18 2015-05-21 Bair Kenneth W Tetrahydroquinoline compositions as bet bromodomain inhibitors
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
EP3448520A4 (en) * 2016-04-29 2020-07-29 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
AU2021325927A1 (en) 2020-08-14 2023-02-23 Minerva Neurosciences, Inc. Condensed azacycles as sigma ligand compounds and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614965B2 (en) * 1987-06-06 1991-09-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
EP0639567A1 (en) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Indole derivative
DE69530690T2 (de) 1994-06-15 2004-03-18 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
WO1998040385A1 (en) * 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
PL336628A1 (en) 1997-05-03 2000-07-03 Smithkline Beecham Plc Derivatives of tetrahydroisoquinoline as modulators of d3 dopamine receptors
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
ATE259363T1 (de) * 1999-09-25 2004-02-15 Smithkline Beecham Plc Piperazinderivate als 5-ht1b antagonisten
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
NZ521192A (en) * 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
AU8112101A (en) * 2000-08-08 2002-02-18 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines
AU2001292936A1 (en) * 2000-09-22 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
EP1395563B1 (en) * 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7381719B2 (en) 2002-09-19 2008-06-03 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0224083D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1554260A1 (en) 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands

Also Published As

Publication number Publication date
AU2003278119A1 (en) 2004-05-13
DE60309913D1 (de) 2007-01-04
US20070105838A1 (en) 2007-05-10
EP1554243A1 (en) 2005-07-20
GB0224557D0 (en) 2002-11-27
ES2276125T3 (es) 2007-06-16
TW200418839A (en) 2004-10-01
JP2006505623A (ja) 2006-02-16
ATE346044T1 (de) 2006-12-15
GB0306328D0 (en) 2003-04-23
US7446103B2 (en) 2008-11-04
DE60309913T2 (de) 2007-06-28
US20090042862A1 (en) 2009-02-12
EP1554243B1 (en) 2006-11-22
WO2004037788A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR042542A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y proceso para su preparacion
AR038966A1 (es) Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR033306A1 (es) Compuestos
WO2002089800A3 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR038420A1 (es) Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
AR038240A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
BR1100514A (pt) Processo para a preparação de compostos derivados do ácido benzimidazolino - 2 - oxo - 1 - carboxìlico; produto / composto / composição
AR051091A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR035325A1 (es) Derivados de adamantano, un proceso para su preparacion, composicion farmaceutica, un proceso para la preparacion de dicha composicion, y el uso de dichos derivados para la fabricacion de un medicamento
CA2570807A1 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AR065927A1 (es) Derivados de 5,6-dihidro-1h-piridin-2-ona
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR038249A1 (es) Compuestos derivados de quinolina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos derivados en la preparacion de un medicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure